PMID- 21162800
OWN - NLM
STAT- MEDLINE
DCOM- 20110728
LR  - 20181201
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 90
IP  - 40
DP  - 2010 Nov 2
TI  - [Effect of telmisartan on tubulointerstitial injury and expression of PPARgamma in 
      rat renal tissue of IgA nephropathy model].
PG  - 2860-3
AB  - OBJECTIVE: To observe the effect of telmisartan on the expression of PPARgamma in rat 
      renal tissue of IgA nephropathy model and clarify the possible mechanism of 
      telmisartan in tubulointerstitial injury. METHODS: The experimental rat model 
      with IgA nephropathy was induced by bovine serum albumin (BSA), 
      lipopolysaccharide (LPS) and carbon tetrachloride (CCl4). Forty male SD rats were 
      randomly divided into control group, IgA model group, rosiglitazone group, 
      telmisartan group and losartan group. At pre-administration, Weeks 4, 8 and 10, 
      the quantity of 24-hour proteinuria was measured. The morphologic changes of 
      renal tissues were evaluated by electron microscope. Immunohistochemistry was 
      used to observe the expressions of PPARgamma, TGF-beta1 and alpha-smooth muscle actin 
      (alpha-SMA) in different groups and RT-PCR to detect the expressions of PPARgamma, TGF-beta1 
      and monocyte chemoattractant protein-1 (MCP-1) in different groups. RESULTS: 
      Compared with control group, 24-hour proteinuria(mg) increased markedly in IgA 
      model group (14.14 +/- 1.99 vs 1.59 +/- 0.18), but rosiglitazone group (2.35 +/- 0.33), 
      telmisartan group (1.88 +/- 0.09) and losartan group (2.82 +/- 0.34) was much lower 
      and telmisartan had the most significant effect (all P < 0.05). Compared with 
      control group, there were varying degrees of mesangial proliferation and 
      infiltration of inflammatory cell in IgA model group (3.10 +/- 0.18). The 
      tubulointerstitial injury was notably alleviated in rosiglitazone group (1.97 +/- 
      0.23), telmisartan group (1.57 +/- 0.14) and losartan group (2.15 +/- 0.22) while 
      telmisartan had the most significant effect (all P < 0.01). With 
      immunohistochemistry and reverse transcription-polymerase chain reaction 
      (RT-PCR), PPARgamma, TGF-beta1, alpha-SMA and MCP-1 had minimal expression on tubule and 
      interstitium in normal group. But there was a high expression in model group. 
      There was no difference between losartan and model groups. There was a lowered 
      expression in rosiglitazone and telmisartan groups. CONCLUSION: Possibly through 
      two separate passway of stimulating PPARgamma and preventing Angiotensin II receptor, 
      telmisartan shows special protective function in tubulointerstitial injury.
FAU - Xing, Li
AU  - Xing L
AD  - Division of Nephrology, Harbin Medical University, Harbin 150001, China.
FAU - Bai, Lin
AU  - Bai L
FAU - Yu, Cheng-yuan
AU  - Yu CY
FAU - Xie, Ru-juan
AU  - Xie RJ
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Benzimidazoles)
RN  - 0 (Benzoates)
RN  - 0 (PPAR gamma)
RN  - U5SYW473RQ (Telmisartan)
SB  - IM
MH  - Animals
MH  - Benzimidazoles/*pharmacology
MH  - Benzoates/*pharmacology
MH  - Glomerulonephritis, IGA/*metabolism/pathology
MH  - Kidney/metabolism
MH  - Kidney Tubules/*drug effects/*metabolism/pathology
MH  - Male
MH  - PPAR gamma/*metabolism
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Telmisartan
EDAT- 2010/12/18 06:00
MHDA- 2011/07/29 06:00
CRDT- 2010/12/18 06:00
PHST- 2010/12/18 06:00 [entrez]
PHST- 2010/12/18 06:00 [pubmed]
PHST- 2011/07/29 06:00 [medline]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2010 Nov 2;90(40):2860-3.